Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.

Pharmacogenetics and genomics - 1 Jul 2008

Fan Lu, Goh Boon-Cher, Wong Chiung-Ing, Sukri Norita, Lim Siew-Eng, Tan Sing-Huang, Guo Jia-Yi, Lim Robert, Yap Hui-Ling, Khoo Yok-Moi, Iau Philip, Lee How-Sung, Lee Soo-Chin

Abstract excerpt

OBJECTIVES: Doxorubicin is a cytotoxic drug with potential for severe myelosuppression that is highly variable and poorly predictable. METHODS: We correlated CBR1 and CBR3 genotypes with the pharmacokinetics and pharmacodynamics of doxorubicin in 101 Southeast Asian breast cancer patients receiving first-line doxorubicin. RESULTS: A common CBR3 11G>A variant was associated with lower doxorubicinol area under the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Doxorubicin

Share to Ethnicity

Share to Genetic Linkage

Share to Inactivation, Metabolic

Share to Leukocytes

Source

Identifiers

PMID: 18551042
DOI: 10.1097/FPC.0b013e328301a869

Genes

CBR3
CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.PMID 18551042Read ↗

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.Semantic proximity Read ↗

Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Semantic proximity Read ↗

Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.Semantic proximity Read ↗

Pharmacogenetics of genes across the doxorubicin pathway.Semantic proximity Read ↗

Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and EfficacySemantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A ReviewSemantic proximity Read ↗

Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.Semantic proximity Read ↗

Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.Semantic proximity Read ↗

Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.